Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	B-Chemical
,	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O

Uni	O
-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B-Disease
,	O
myocardiopathy	B-Disease
(	O
MP	B-Disease
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-Disease
regurgitation	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	B-Chemical
dose	O
.	O

Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	B-Disease
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	B-Disease
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

NRA0160	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
thiazole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	B-Chemical
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

However	O
,	O
increased	O
dyspnoea	B-Disease
and	O
bronchospasm	B-Disease
necessitated	O
reintubation	O
.	O

Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	B-Chemical
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B-Disease
glomerulopathy	I-Disease
and	O
interstitial	B-Disease
nephritis	I-Disease
.	O

He	O
bought	O
25	O
g	O
of	O
carbachol	B-Chemical
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O

In	O
several	O
models	O
of	O
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	B-Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B-Disease
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

HBsAg	B-Chemical
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Guillain	B-Disease
-	I-Disease
Barr	I-Disease
syndrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Disease
neuropathy	I-Disease
.	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
infection	I-Disease
.	O

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	B-Chemical
.	O

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
bupivacaine	B-Chemical
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O

Reactions	O
consisted	O
mainly	O
of	O
seizures	B-Disease
,	O
acute	O
psychoses	B-Disease
,	O
anxiety	B-Disease
neurosis	I-Disease
,	O
and	O
major	O
disturbances	B-Disease
of	I-Disease
sleep	I-Disease
-	I-Disease
wake	I-Disease
rhythm	I-Disease
.	O

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

Five	O
patients	O
displayed	O
CAN	B-Disease
and	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
who	O
developed	O
severe	O
intrahepatic	B-Disease
cholestasis	I-Disease
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-Disease
abscess	I-Disease
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
PCP	B-Disease
.	O

The	O
typical	O
signs	O
of	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
are	O
impaired	B-Disease
consciousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B-Disease
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B-Disease
.	O

The	O
majority	O
of	O
these	O
aneurysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
.	O

None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	O
.	O

The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O

Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positive	O
and	O
an	O
HBeAg	B-Chemical
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

Ecstasy	B-Chemical
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

B6	O
mice	O
were	O
resistant	O
to	O
seizures	B-Disease
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O

Because	O
of	O
the	O
extreme	O
toxicity	B-Disease
of	O
vitamin	B-Chemical
D3	I-Chemical
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
that	O
prevent	O
milk	B-Disease
fever	I-Disease
and	O
doses	O
that	O
induce	O
milk	B-Disease
fever	I-Disease
,	O
we	O
concluded	O
that	O
vitamin	B-Chemical
D3	I-Chemical
cannot	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-Disease
fever	I-Disease
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O

Increased	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
with	O
the	O
combination	O
of	O
docetaxel	B-Chemical
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O

Flestolol	B-Chemical
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	B-Chemical
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloquine	B-Chemical
users	O
suffers	O
from	O
such	O
reactions	O
.	O

Preparations	O
containing	O
lindane	B-Chemical
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	B-Chemical
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	B-Chemical
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

After	O
the	O
administration	O
of	O
NG	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
CY	B-Chemical
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	B-Chemical
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	B-Chemical
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	B-Chemical
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	B-Chemical
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	B-Chemical
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Srl	B-Chemical
should	O
be	O
used	O
with	O
ACEi	B-Chemical
/	O
ARB	B-Chemical
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	B-Disease
and	O
increased	O
renal	B-Disease
dysfunction	I-Disease
.	O

High	O
doses	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

Sex	O
differences	O
in	O
NMDA	B-Chemical
antagonist	O
enhancement	O
of	O
morphine	B-Chemical
antihyperalgesia	O
in	O
a	O
capsaicin	B-Chemical
model	O
of	O
persistent	O
pain	B-Disease
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-Disease
pain	I-Disease
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	B-Chemical
,	O
the	O
dose	O
-	O
limiting	O
toxicities	B-Disease
associated	O
with	O
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	B-Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O

METHODS	O
:	O
All	O
PD	B-Disease
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B-Disease
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-Chemical
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-Disease
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	B-Chemical
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-Disease
injury	I-Disease
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	B-Chemical
hydrochloride	I-Chemical
ophthalmic	O
solution	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O

Treatment	O
for	O
ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-Chemical
treatment	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	B-Chemical
.	O

METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
were	O
randomised	O
to	O
alprazolam	B-Chemical
or	O
placebo	O
.	O

Thirty	O
-	O
four	O
patients	O
with	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	B-Chemical
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B-Disease
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

The	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-Chemical
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	B-Chemical
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B-Disease
after	O
cocaine	B-Chemical
use	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	B-Chemical
,	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B-Disease
who	O
developed	O
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	B-Chemical
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	B-Disease
.	O

After	O
drug	O
administration	O
,	O
creatinine	B-Chemical
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	B-Chemical
clearance	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	B-Chemical
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	B-Chemical
such	O
as	O
drug	O
-	O
induced	O
hypothermia	B-Disease
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blockade	O
obtained	O
with	O
risperidone	B-Chemical
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O

Depressed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-Disease
.	O

The	O
morphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
potentiated	O
by	O
scopolamine	B-Chemical
and	O
attenuated	O
by	O
physostigmine	B-Chemical
.	O

Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	B-Chemical
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	B-Chemical
syndrome	O
in	O
case	O
of	O
alcohol	B-Chemical
use	O
.	O

In	O
vitro	O
,	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pentylenetetrazol	B-Chemical
and	O
picrotoxin	B-Chemical
were	O
shown	O
to	O
inhibit	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

A	O
nonregenerative	O
anemia	B-Disease
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	B-Chemical
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazedone	B-Chemical
.	O

A	O
significant	O
proportion	O
of	O
warfarin	B-Chemical
-	O
related	O
cerebral	B-Disease
haemorrhages	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	B-Chemical
.	O

We	O
report	O
a	O
case	O
of	O
atracurium	B-Chemical
-	O
related	O
paralysis	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O

INTERPRETATION	O
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
within	O
FS	O
.	O

RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B-Disease
,	O
sweating	O
and	O
hypotension	B-Disease
,	O
and	O
finally	O
collapsed	O
.	O

Suxamethonium	B-Chemical
chloride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
administered	O
i	O
.	O
v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	B-Chemical
,	O
in	O
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

The	O
hypotensive	B-Disease
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	B-Chemical
s	O
.	O
c	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	B-Disease
mouth	I-Disease
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	B-Chemical
administered	O
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

Focal	O
glutamate	B-Chemical
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	B-Disease
survivors	O
but	O
not	O
other	O
groups	O
.	O

Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
.	O

Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	B-Chemical
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	B-Chemical
for	O
vasospasm	B-Disease
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	B-Chemical
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

Hemolysis	B-Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	B-Disease
or	O
dislocation	B-Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	B-Chemical
mole	O
fraction	O
was	O
unchanged	O
.	O

UM	B-Chemical
-	I-Chemical
272	I-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
-	I-Chemical
dimethylpropranolol	I-Chemical
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	B-Chemical
-	O
induced	O
ventricular	B-Disease
tachycardias	I-Disease
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	O
the	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

A	O
single	O
MPEP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	B-Chemical
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	O
stimulated	O
either	O
by	O
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-Disease
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B-Disease
response	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
in	O
a	O
single	O
pediatric	O
institution	O
.	O

Choreatiform	B-Disease
hyperkinesias	I-Disease
are	O
known	O
to	O
be	O
occasional	O
movement	B-Disease
abnormalities	I-Disease
during	O
intoxications	O
with	O
cocaine	B-Chemical
but	O
not	O
opiates	O
.	O

Infarct	B-Disease
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-Chemical
.	O

The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O

The	O
rats	O
treated	O
with	O
DFP	B-Chemical
-	O
atropine	B-Chemical
showed	O
severe	O
typical	O
OP	B-Chemical
-	O
induced	O
toxicity	B-Disease
signs	O
.	O

AV	B-Disease
block	I-Disease
,	O
severe	O
hypotension	B-Disease
,	O
and	O
impairment	B-Disease
of	I-Disease
ventricular	I-Disease
function	I-Disease
.	O

Testosterone	B-Chemical
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	B-Chemical
system	O
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Chemical
sodium	I-Chemical
indicated	O
that	O
indocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fluorescein	B-Chemical
for	O
use	O
in	O
angiography	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Optimising	O
stroke	B-Disease
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B-Disease
fibrillation	I-Disease
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Threo	I-Chemical
-	I-Chemical
dihydroxyphenylserine	I-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-Disease
-	O
associated	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	B-Chemical
-	O
treated	O
group	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

Subjects	O
also	O
recalled	O
their	O
pains	B-Disease
one	O
week	O
later	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	B-Chemical
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	B-Chemical
excretion	O
to	O
control	O
values	O
.	O

Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-Disease
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
,	O
neuropsychiatric	B-Disease
symptoms	I-Disease
,	O
and	O
nonhemorrhagic	O
cerebral	B-Disease
infarction	I-Disease
.	O

Epinephrine	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cardiac	B-Disease
arrest	I-Disease
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-Disease
reaction	I-Disease
and	O
severe	O
hypertension	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O

High	O
-	O
dose	O
testosterone	B-Chemical
is	O
associated	O
with	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O

Erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

Long	O
-	O
term	O
glutamate	B-Chemical
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
paclitaxel	B-Chemical
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	B-Chemical
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O

Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Chemical
diphosphate	I-Chemical
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O

Glyburide	B-Chemical
can	O
produce	O
an	O
acute	B-Disease
hepatitis	I-Disease
-	I-Disease
like	I-Disease
illness	I-Disease
in	O
some	O
persons	O
.	O

Coniine	B-Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B-Disease
was	O
noted	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	B-Chemical
may	O
produce	O
neurological	B-Disease
complications	I-Disease
,	O
including	O
confusion	B-Disease
,	O
altered	O
mental	O
status	O
,	O
seizures	B-Disease
,	O
and	O
coma	B-Disease
,	O
particularly	O
in	O
older	O
women	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	B-Disease
or	O
mania	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-Disease
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B-Disease
episodes	O
.	O

A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B-Disease
male	O
taking	O
thyroxine	B-Chemical
and	O
simvastatin	B-Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	B-Chemical
does	O
not	O
cause	O
hemolytic	B-Disease
anemia	I-Disease
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
,	O
using	O
Tc99m	B-Chemical
-	I-Chemical
Sestamibi	I-Chemical
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-Disease
.	O

The	O
recreational	O
use	O
of	O
cocaine	B-Chemical
is	O
on	O
the	O
increase	O
.	O

Pain	B-Disease
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
duration	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

After	O
discontinuing	O
isoniazid	B-Chemical
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	B-Chemical
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nicotine	B-Chemical
sulfate	O
-	O
treated	O
chicks	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	B-Chemical
toxicity	B-Disease
were	O
seen	O
.	O

Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
finding	O
that	O
VPU	B-Chemical
could	O
drastically	O
reduce	O
pilocarpine	B-Chemical
-	O
induced	O
increases	O
in	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
in	O
experimental	O
animals	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
progesterone	B-Chemical
or	O
vehicle	O
(	O
0	O
.	O
01	O
%	O
ethanol	B-Chemical
)	O
.	O

Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

Glyburide	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O

Evidence	O
is	O
accumulating	O
that	O
lindane	B-Chemical
can	O
be	O
toxic	B-Disease
to	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
and	O
may	O
be	O
associated	O
with	O
aplastic	B-Disease
anaemia	I-Disease
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	B-Chemical
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B-Disease
headache	B-Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	B-Chemical
and	O
migraine	B-Disease
.	O

Death	B-Disease
from	O
chemotherapy	O
in	O
gestational	B-Disease
trophoblastic	I-Disease
disease	I-Disease
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

VNB	B-Chemical
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B-Disease
occurred	O
.	O

